MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Simulations Plus (SLP) and Mediwound (MDWD) with bul...

Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP) and Mediwound (MDWD)

The latest announcement is out from Mediwound ( ($MDWD) ). On April 2, 2026, MediWound reported that its North American partner Vericel secured a t...

MediWound Highlights Vericel’s $197 Million BARDA Contract for NexoBrid

Mediwound ( ($MDWD) ) has shared an announcement. On March 30, 2026, MediWound filed a Form 6-K announcing it had published proxy materials and not...

MediWound Sets May 6, 2026 Shareholder Meeting to Vote on Board, Auditor and CEO Bonus

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cullinan Management (CGEM – Research Report) and Med...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDWD	$17.20	+1.36%	93.66K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDWD	$17.20	+1.4%	93.66K
3
4
5
6

MDWD

MDWD

Get MediWound Ltd. Data in Excel

Get MediWound Ltd. Data in Excel